Icon	Function
💬	A pop-up explanation appears when you mouse-over the text beside this icon. Also, an explanation window appears when you click this icon.
	The links beside this icon are links to external sites.
	Clicking this icon sorts the table by the item with this icon (Numerical or alphabetical order). Each click toggles between ascending and descending order.
	A text longer than 100 characters is fully displayed or collapsed.
	The contents of the displayed table are downloaded as a file named "table.csv".

DR info

Clinical trials : 9 / Drugs : 8 - (DrugBank : 3) / Drug target genes : 9 - Drug target pathways : 16

Drugs, Primary sponsors and Trial info (Enrollment year, Phase, Trial ID, Countries)

Copper
   Hamamatsu University School of Medicine
      2014   -   JPRN-UMIN000030626   Japan
   Kobe Unniversitu Graduate School of Medicine
      2011   -   JPRN-UMIN000005259   Japan
Copper histidinate
   Sentynl Therapeutics, Inc.
      2020   -   NCT04074512   United States
Copper histidine
   Cyprium Therapeutics, Inc.
      2009   Phase 3   NCT00811785   United States
   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
      1990   Phase 1/Phase 2   NCT00001262   United States
Droxidopa
   Stephen G. Kaler, MD
      2021   Phase 1/Phase 2   NCT04977388   United States
Droxidopa oral product
   Stephen G. Kaler
      2026   Phase 1/Phase 2   NCT07398508   United States
Histidine
   Hamamatsu University School of Medicine
      2014   -   JPRN-UMIN000030626   Japan
   Kobe Unniversitu Graduate School of Medicine
      2011   -   JPRN-UMIN000005259   Japan
Long term follow-UP
   Sentynl Therapeutics, Inc.
      2019   -   NCT04337684   United States
Recombinant adeno-associated virus administration
   Kunming Hope of Health Hospital
      2022   Early Phase 1   NCT05507996   China